Physician profile
Muhammad Pervaiz
NPI 1417174186
$588.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $52.24 · 2021: $141 · 2022: $141 · 2024: $21.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $100.15 | 2021 | |
| Biomarin Pharmaceutical INC. | $97.49 | 2022 | |
| Biogen, INC. | $64.90 | 2021-2022 | |
| Melinta Therapeutics, LLC | $56.63 | 2019-2020 | |
| Amicus Therapeutics, INC. | $48.86 | 2019-2020 | |
| Pfizer INC. | $45.42 | 2019 | |
| Genzyme Corporation | $40.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.60 | 2019 | |
| Gilead Sciences, INC. | $21.99 | 2024 | |
| Shire North American Group INC | $20.32 | 2019 | |
| Vapotherm INC | $19.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Pervaiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.